[HTML][HTML] Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Major cardiovascular outcome trials and real-life observations have proven that glucagon-
like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 …
like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 …
[HTML][HTML] Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with …
A Ahmad, H Sabbour - Cardiovascular Diabetology, 2024 - Springer
Background Randomized controlled trials and real-world studies suggest that combination
therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like …
therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like …
[HTML][HTML] Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes
C Luna-Marco, AM de Marañon, A Hermo-Argibay… - Redox Biology, 2023 - Elsevier
Abstract Objective Type 2 diabetes (T2D) is linked to metabolic, mitochondrial and
inflammatory alterations, atherosclerosis development and cardiovascular diseases (CVDs) …
inflammatory alterations, atherosclerosis development and cardiovascular diseases (CVDs) …
[HTML][HTML] GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients …
Background Few studies explored the effect of the combination of glucose sodium-
cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP …
cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP …
[HTML][HTML] Meta-analysis assessing the effectiveness of SGLT2i+ GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in …
L Du, J Qin, D Wang, Y Zhao, N Xu, C Wu… - Frontiers in …, 2022 - frontiersin.org
Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists …
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists …
Treating chronic kidney disease to reduce cardiovascular risk
Chronic kidney disease (CKD) is a complex syndrome and a relevant problem of public
health due to its large incidence and prevalence and to the high costs for its management …
health due to its large incidence and prevalence and to the high costs for its management …
[PDF][PDF] La gestione del paziente con diabete di tipo 2 in Cardiologia Preventiva e Riabilitativa. Expert opinion della Italian Alliance for Cardiovascular Rehabilitation …
M Ambrosetti, F Fattirolli, F Maranta, M Ruzzolini… - G Ital …, 2023 - researchgate.net
Patients with diabetes, regardless of their cardiovascular disease and their index event, are
more and more often referred to Cardiac Rehabilitation Units. These patients usually show …
more and more often referred to Cardiac Rehabilitation Units. These patients usually show …
[HTML][HTML] The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …
[PDF][PDF] The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney
Background To determine whether glucagon‑like peptide 1 receptor agonists (GLP‑1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …